A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols.
Phase of Trial: Phase II
Latest Information Update: 27 Jun 2017
At a glance
- Drugs Tivozanib (Primary) ; Capecitabine; Paclitaxel; Temsirolimus
- Indications Breast cancer; Renal cell carcinoma; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors AVEO Oncology
- 18 Aug 2016 Status changed from active, no longer recruiting to completed.
- 22 Jun 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 08 Aug 2013 New source identified and integrated (University of Southern California Norris Comprehensive Cancer Center, 4K12-5).